U.S. FDA seeks additional info on drug from Richter partner
Pharmaceuticals firm Gedeon Richter says that the U.S. Food and Drug Administration (FDA) has requested additional information from its partner Allergan in response to the latterʼs New Drug Application (NDA) for ulipristal acetate (UPA) for the treatment of uterine fibroids. UPA is the active ingredient of Richterʼs drug Esmya.
The FDA said it is not able to approve the ulipristal acetate NDA in its current form, according to Hungarian news agency MTI. The agency cited safety concerns regarding Esmya post-marketing reports outside the United States. Allergan plans to meet with the FDA to discuss their comments and the next steps.
The European Commission (EC) made a resolution at the end of July regarding the distribution of Esmya after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion on the matter on June 1. The EC specified amended conditions for the drugʼs distribution license.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.